Anti-Human CD19 (104882) h(CD28-41BB-CD3Z) CAR Lentivirus Packaging Kit (XS-0622-YF130)

Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This kit provides a complete lentivirus packaging system to produce anti-CD19 (104882) h(4-1BB-CD3ζ) CAR lentivirus, which enables CAR-T cells generation to target Human CD19. It contains plasmids that express all the viral proteins necessary, and CAR detection reagent, providing a full set of reagents for CAR lentivirus packaging and CAR expression evaluation. The expressed anti-CD19 CAR lentiviruses are HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells. These viruses constitutively express the scFv portion of anti-CD19 (104882) linked to 3nd generation CAR containing CD28, 41BB and CD3ζ signaling domains. CAR detection reagent can be used to detect the positive expression rate of CAR-T cells after lentiviral transduction.

Add to Cart

Description

Target
CD19

Components
This kit contains a CAR lentiviral vector, packaging vectors, CAR detection reagent, and 293 cells.
1. A CAR lentiviral vector
• Anti-CD19 (104882) h(CD28-41BB-CD3ζ) CAR
2. Three packaging vectors
• LentiArt™ pHelp1
• LentiArt™ pHelp2
• LentiArt™ pHelp3
3. CAR detection reagent
4. 293 cells

Size
10 reactions; 20 reactions; 50 reactions

Storage Conditions
For details of the storage requirements, please see the User Manual for instructions.

Applications
CAR lentivirus packaging; CAR lentivirus transfection; CAR-T cell development; CAR-T cell therapy.

CAR Vector

CAR Generation
3nd-generation CAR

Vector Name
pCDCAR1

Vector Length
~8kb

Vector Type
Lentiviral vector

Receptor Construction
scFv-CD28-41BB-CD3ζ

Target

Gene Name
CD19

Full Name
CD19 Molecule

scFv
104882

Host Species
Human

Target Species
Human

Gene ID
930

Uniprot ID
P15391

Target Background
This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Synonyms
CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; B-Lymphocyte Antigen CD19; CVID3; B4

Related Disease
Chronic lymphocytic leukemia (CLL)

Related Resources

Overview of CD19-Targeted CAR Cell Therapies

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-Human CD19 (104882) h(CD28-41BB-CD3Z) CAR Lentivirus Packaging Kit (XS-0622-YF130). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.